New injection may simplify ventral hernia repair, avoid complex surgery

NCT ID NCT07226791

Recruiting now Symptom relief Sponsor: AbbVie Source: ClinicalTrials.gov ↗

First seen Nov 10, 2025 · Last updated May 03, 2026 · Updated 25 times

Summary

This study tests an investigational drug called AGN-151607-DP (gemibotulinumtoxinA) to see if it can help close the belly wall after open ventral hernia surgery without needing a complex additional procedure. About 200 adults with a midline ventral hernia will receive either the drug or a placebo injection. The goal is to make surgery simpler and safer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for VENTRAL HERNIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

CARI Clinical Trials INC /ID# 278844
RECRUITING

Riverside, California, 92504, United States
Medical Research Center /ID# 278680
RECRUITING

Miami, Florida, 33144, United States
NextStage Clinical Research-Evergreen Surgical /ID# 278710
RECRUITING

Eau Claire, Wisconsin, 54701, United States
University of Florida - Jacksonville /ID# 261992
RECRUITING

Jacksonville, Florida, 32209, United States

Conditions

Explore the condition pages connected to this study.

VENTRAL HERNIA